3 Questions: What’s next for local and campus-based Covid-19 policies and protocols?
With federal and state public health emergencies expiring on May 11, Cecilia Stuopis and Ian Waitz discuss the next chapter for MIT.
With federal and state public health emergencies expiring on May 11, Cecilia Stuopis and Ian Waitz discuss the next chapter for MIT.
Ali Jadbabaie and Robert van der Hilst discuss how a new joint degree program in climate system science and engineering will prepare students to solve global-scale environmental problems.
MIT’s dean of admissions and student financial services talks about helping rural students better understand their options for going to college.
MIT CSHub Deputy Director Hessam AzariJafari is conducting vital research to investigate the impacts of concrete's carbonation across its life cycle.
MIT scholars discuss the history behind the war, lessons learned on state-building, and Iraq’s current political outlook.
Work of the Future Initiative co-directors Julie Shah and Ben Armstrong describe their vision of “positive-sum automation.”
A new campus series intends to inspire conversation about building community across the Institute.
On March 10 the FDA approved Trofinetide, a drug based on the protein IGF-1. The MIT professor's original research showing that IGF-1 could treat Rett was published in 2009.
The MIT Energy Initiative’s director of education shares new initiatives aimed at preparing students to take an active role in solving the climate crisis.
Saverio Cambioni discusses new results revealing the redirected asteroid Dimorphos to be a dust-trailing rubble-pile.
The MLK Visiting Professor studies the ways innovators are influenced by their communities.
MIT composer’s piece premieres at Lincoln Center on March 7, with superstar Joyce DiDonato in a leading — and surprising — role.
Frederick Harris Jr., MIT senior lecturer and creator of the It Must Be Now! initiative, reflects on music’s historic role in addressing racial issues.
The chatbot’s success on the medical licensing exam shows that the test — and medical education — are flawed, Celi says.
The associate professor of MechE reflects on how his company, Kytopen, has grown and shifted focus in developing safer immunotherapies.